Becton, Dickinson and Company (BDX) Projected to Post Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to release its earnings data before the market opens on Thursday, February 6th. Analysts expect Becton, Dickinson and Company to post earnings of $3.00 per share and revenue of $5.13 billion for the quarter. Becton, Dickinson and Company has set its FY 2025 guidance at 14.250-14.600 EPS and its FY25 guidance at $14.25-14.60 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm posted $3.42 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of BDX opened at $247.57 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The firm has a market capitalization of $71.80 billion, a PE ratio of 41.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The stock’s fifty day simple moving average is $230.53 and its 200-day simple moving average is $233.83.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares in the company, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.